Evidence map›Paper›PMID 37053049›Full record

ArticleAmerican journal of physiology. Endocrinology and metabolism2023

Central androgen action reverses hypothalamic astrogliosis and atherogenic risk factors induced by orchiectomy and high-fat diet feeding in male mice.

Mauricio D Dorfman, Thomas Monfeuga, Susan J Melhorn, Jenny E Kanter, Jeremy M Frey, Rachael D Fasnacht, Anandhakumar Chandran, Emaad Lala, Inmaculada Velasco, Katya B Rubinow and 4 more

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Endocrinology and metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Mauricio D DorfmanUW Medicine Diabetes Institute, University of Washington, Seattle, Washington, United States.ORCID 0000-0002-9587-0564
Thomas MonfeugaNovo Nordisk Research Centre Oxford, Oxford, United Kingdom.
Susan J MelhornUW Medicine Diabetes Institute, University of Washington, Seattle, Washington, United States.
Jenny E KanterUW Medicine Diabetes Institute, University of Washington, Seattle, Washington, United States.
Jeremy M FreyUW Medicine Diabetes Institute, University of Washington, Seattle, Washington, United States.
Rachael D FasnachtUW Medicine Diabetes Institute, University of Washington, Seattle, Washington, United States.
Anandhakumar ChandranNovo Nordisk Research Centre Oxford, Oxford, United Kingdom.
Emaad LalaUW Medicine Diabetes Institute, University of Washington, Seattle, Washington, United States.
Inmaculada VelascoUW Medicine Diabetes Institute, University of Washington, Seattle, Washington, United States.
Katya B RubinowUW Medicine Diabetes Institute, University of Washington, Seattle, Washington, United States.ORCID 0000-0002-6505-5657
Thomas H MeekNovo Nordisk Research Centre Oxford, Oxford, United Kingdom.
Ellen A SchurUW Medicine Diabetes Institute, University of Washington, Seattle, Washington, United States.ORCID 0000-0002-1013-0795
Karin E BornfeldtUW Medicine Diabetes Institute, University of Washington, Seattle, Washington, United States.
Joshua P ThalerUW Medicine Diabetes Institute, University of Washington, Seattle, Washington, United States.
University of Washington · USNovo Nordisk (United Kingdom) · GB

Funding

Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Sakeneh Zraika · 1986 to 2026
$41.4M
PILOT STUDY--CLINICAL NUTRITION RESEARCHP30DK035816 · NIDDK · UNIVERSITY OF WASHINGTON · PI Ellen A Schur · 1986 to 2026
$30.4M
Diabetes, Obesity and Metabolism Training ProgramT32DK007247 · NIDDK · UNIVERSITY OF WASHINGTON · PI GREGORY J MORTON, KRISTINA Marie UTZSCHNEIDER · 1986 to 2026
$10.0M
Identifying new strategies for prevention of cardiovascular complications of diabetesR35HL150754 · NHLBI · UNIVERSITY OF WASHINGTON · PI BORNFELDT, KARIN E · 2020 to 2025
$6.2M
Metabolic Regulation by Microglial Inflammatory SignalingR01DK119754 · NIDDK · UNIVERSITY OF WASHINGTON · PI JOSHUA P THALER · 2018 to 2026
$5.1M
Lipid-associated macrophages in diabetic kidney diseaseR01DK121756 · NIDDK · UNIVERSITY OF WASHINGTON · PI Jenny E. Kanter · 2020 to 2026
$2.7M
Fostering patient-oriented research in cardiometabolic disease pathogenesis and preventionK24HL144917 · NHLBI · UNIVERSITY OF WASHINGTON · PI Ellen A Schur · 2019 to 2026
$965k
Role of estrogens in hypothalamic inflammation and metabolic regulation.R21DK127296 · NIDDK · UNIVERSITY OF WASHINGTON · PI DORFMAN, MAURICIO D · 2021 to 2023
$662k
Central regulation of atherosclerosis by testosterone-deficiencyK01HL153205 · NHLBI · UNIVERSITY OF WASHINGTON · PI DORFMAN, MAURICIO D · 2021 to 2024
$648k
NHLBI NIH HHS K01 HL153205NHLBI NIH HHS K24 HL144917NHLBI NIH HHS R35 HL150754NIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK035816NIDDK NIH HHS R01 DK119754NIDDK NIH HHS R01 DK121756NIDDK NIH HHS R21 DK127296NIDDK NIH HHS T32 DK007247
6 · The paper itself

Abstract

Hypogonadism in males confers elevated cardiovascular disease (CVD) risk by unknown mechanisms. Recent radiological evidence suggests that low testosterone (T) is associated with mediobasal hypothalamic (MBH) gliosis, a central nervous system (CNS) cellular response linked to metabolic dysfunction. To address mechanisms linking CNS androgen action to CVD risk, we generated a hypogonadal, hyperlipidemic mouse model with orchiectomy (ORX) combined with hepatic PCSK9 overexpression. After 4 wk of high-fat, high-sucrose diet (HFHS) consumption, despite equal body weights and glucose tolerance, androgen-deficient ORX mice had a more atherogenic lipid profile and increased liver and leukocyte inflammatory signaling compared with sham-operated control mice. Along with these early CVD risk indicators, ORX markedly amplified HFHS-induced astrogliosis in the MBH. Transcriptomic analysis further revealed that ORX and high-fat diet feeding induced upregulation of inflammatory pathways and downregulation of metabolic pathways in hypothalamic astrocytes. To interrogate the role of sex steroid signaling in the CNS in cardiometabolic risk and MBH inflammation, central infusion of T and dihydrotestosterone (DHT) was performed on ORX mice. Central DHT prevented MBH astrogliosis and reduced the liver inflammatory signaling and monocytosis induced by HFHS and ORX; T had a partial protective effect. Finally, a cross-sectional study in 41 adult men demonstrated a positive correlation between radiological evidence of MBH gliosis and plasma lipids. These findings demonstrate that T deficiency in combination with a Western-style diet promotes hypothalamic gliosis concomitant with increased atherogenic risk factors and provide supportive evidence for regulation of lipid metabolism and cardiometabolic risk determinants by the CNS action of sex steroids.

Indexed as

AndrogensCardiovascular DiseasesAnimalsCross-Sectional StudiesDiet, High-FatDihydrotestosteroneGliosisHumansMaleMiceOrchiectomyProprotein Convertase 9Risk FactorsAndrogensDihydrotestosteronePCSK9 protein, humanProprotein Convertase 9astrocytecardiovascular riskhypogonadismhypothalamic gliosistestosterone

Identifiers

PMID37053049
PMCPMC10202485
OpenAlexW4365442618

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.